Zai gains China rights to three MacroGenics immuno-oncology compounds

Zai Lab Ltd. (NASDAQ:ZLAB) bulked up its cancer pipeline Thursday by in-licensing Chinese rights to three immuno-oncology compounds from MacroGenics Inc. (NASDAQ:MGNX), including margetuximab, an Fc optimized mAb against HER2 in Phase III testing for breast cancer.

Zai received exclusive rights in China, Hong Kong, Macau and Taiwan to the therapies, which also include MGD013, a human bispecific antibody against PD-1 and lymphocyte-activation gene 4 (LAG3:CD223); and an undisclosed preclinical candidate developed on MacroGenics' TRIDENT platform. MGD013, which was generated using MacroGenics’ DART technology, is in Phase I trials to treat solid and hematological malignancies...